AGL 37.80 Decreased By ▼ -0.35 (-0.92%)
AIRLINK 129.49 Increased By ▲ 4.42 (3.53%)
BOP 7.38 Increased By ▲ 0.53 (7.74%)
CNERGY 4.62 Increased By ▲ 0.17 (3.82%)
DCL 8.40 Increased By ▲ 0.49 (6.19%)
DFML 38.57 Increased By ▲ 1.23 (3.29%)
DGKC 81.00 Increased By ▲ 3.23 (4.15%)
FCCL 32.75 Increased By ▲ 2.17 (7.1%)
FFBL 74.24 Increased By ▲ 5.38 (7.81%)
FFL 12.35 Increased By ▲ 0.49 (4.13%)
HUBC 109.11 Increased By ▲ 4.61 (4.41%)
HUMNL 13.99 Increased By ▲ 0.50 (3.71%)
KEL 5.05 Increased By ▲ 0.40 (8.6%)
KOSM 7.51 Increased By ▲ 0.34 (4.74%)
MLCF 38.14 Increased By ▲ 1.70 (4.67%)
NBP 71.30 Increased By ▲ 5.38 (8.16%)
OGDC 187.50 Increased By ▲ 7.97 (4.44%)
PAEL 25.25 Increased By ▲ 0.82 (3.36%)
PIBTL 7.39 Increased By ▲ 0.24 (3.36%)
PPL 151.00 Increased By ▲ 7.30 (5.08%)
PRL 25.13 Increased By ▲ 0.81 (3.33%)
PTC 17.12 Increased By ▲ 0.72 (4.39%)
SEARL 82.45 Increased By ▲ 3.88 (4.94%)
TELE 7.56 Increased By ▲ 0.34 (4.71%)
TOMCL 32.90 Increased By ▲ 0.93 (2.91%)
TPLP 8.50 Increased By ▲ 0.37 (4.55%)
TREET 16.50 Increased By ▲ 0.37 (2.29%)
TRG 56.30 Increased By ▲ 1.64 (3%)
UNITY 28.23 Increased By ▲ 0.73 (2.65%)
WTL 1.33 Increased By ▲ 0.04 (3.1%)
BR100 10,544 Increased By 455.1 (4.51%)
BR30 30,955 Increased By 1446.6 (4.9%)
KSE100 98,252 Increased By 3677.4 (3.89%)
KSE30 30,640 Increased By 1195.6 (4.06%)

Playing tailor-made video games can help children with attention deficit hyperactivity disorder (ADHD), according to results from a pivotal clinical trial announced on Monday. The US company developing the treatment, unlisted Akili, now plans to file for regulatory approval with the US Food and Drug Administration in the first half of 2018, paving the way for what would be the first such "digital" prescription product. Akili is an affiliate of London-listed PureTech Health.
Cases of ADHD have been rising around the world in recent decades, with children often given drugs to treat the disorder. Akili's product takes a different approach by using a game to stimulate specific cognitive neural systems in the brain. In the randomised, controlled trial of 348 children and adolescents with ADHD, Akili's product AKL-T01 showed a statistically significant improvement compared with an active control in attention performance. The control was also a video game.
Medicating ADHD is big business, with Shire a leading player in the field. Shire is also an investor in Akili.

Comments

Comments are closed.